Lyra therapeutics appoints jim tobin to board of directors

Watertown, mass., march 7, 2022 /prnewswire/ -- lyra therapeutics, inc. (nasdaq: lyra), a clinical-stage therapeutics company leveraging its proprietary xtreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ent) passages and other diseased tissues, today announced the appointment of jim tobin to its board of directors (bod).
LYRA Ratings Summary
LYRA Quant Ranking